The company has disclosed the activity of Arius’s anti-CD9 antibody, AR40A746.2.3, against acute myeloid leukemia (AML). CD9 appears to be an important driver for leukemia and potentially other cancer stem cells, which often survive treatment, continue to multiply and go on to seed new tumors.
Daniel Pereira, vice president of research at Arius, said: “Our antibody also appears to be a specific cancer stem cell inhibitor, suggesting that it may become an important drug and forge new paths for the treatment of cancer.”